Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07023887

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

Status
Recruiting
Phase
Study type
Observational
Enrollment
15 (estimated)
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Academic / Other
Sex
Female
Age
20 Years – 89 Years
Healthy volunteers
Not accepted

Summary

This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5/5/5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.

Conditions

Interventions

TypeNameDescription
OTHER6-12-25 Training RegimenA conditioning regimen involving three exercises performed consecutively with minimal rest. Includes 4-6 repetitions at 4-0-1-0 tempo, 10-12 repetitions at 3-0-1-0 tempo, and 20-25 repetitions at 2-0-1-0 tempo.
OTHER8x8 Training RegimenA conditioning regimen optimizing high volume with short rest periods. Six exercises are performed consecutively with a 2-0-1-0 tempo and no rest between sets.
OTHER5/5/5 Cluster Set Training RegimenA hypertrophy regimen where an individual performs 5 repetitions at a tempo of 4 seconds during the eccentric movement of the exercise, while performing the concentric motion in 1 second then resting for 20 seconds and repeating the sequence two additional times to total three clusters of 5 repetitions.
OTHERDouble Training RegimenA hypertrophy regimen adding an additional set of lesser repetitions for a specified exercise at the end of a tri-set of exercises.

Timeline

Start date
2025-05-21
Primary completion
2026-07-15
Completion
2026-10-15
First posted
2025-06-17
Last updated
2026-02-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07023887. Inclusion in this directory is not an endorsement.